HASBROUCK HEIGHTS, N.J., June 21 /CNW/ - Nymox Pharmaceutical Corporation
(NASDAQ: NYMX) today announced that detailed results from the Company's
recently completed studies of NX-1207 for benign prostatic hyperplasia (BPH)
will be presented at a series of upcoming U.S. urology meetings, beginning in
September at the South Central American Urological Association Meeting in
Colorado Springs. These independent podium presentations will be given by
leading clinical research urologist principal investigators from the clinical
trials. Further specific details on the upcoming presentations will be
announced at a later date.
The Company has completed a series of studies of the safety and efficacy
of NX-1207 for BPH, including two Phase 1-2 studies and a Phase 2 study as
well as several follow-up studies of patients for up to 3 1/2 years after
NX-1207 treatment. The Company's recently completed prospective randomized
placebo controlled Phase 2 U.S. study confirmed the positive efficacy and
safety results for NX-1207 from earlier studies. After 3 months, patients
treated with NX-1207 had a mean improvement of 9.35 points in AUA Symptom
Score values, the standard scale used to evaluate BPH drugs and treatments.
This improvement was significantly greater than the 3.5 to 5 points typically
reported for currently approved drugs for BPH. The results of the trial
demonstrated the excellent safety and side effect profile of NX-1207. In
particular, patients given NX-1207 had no (0%) significant sexual side
effects. Follow-up studies have provided data showing that NX-1207 can provide
enduring benefits of up to 42 months or more following treatment.
The AUA Symptom Score is a standardized and widely accepted questionnaire
used to assess the severity of BPH symptoms and the efficacy of treatments for
BPH. The AUA Score consists of seven questions relating to frequency of
problems with urination such as urgency, starting and stopping, straining,
poor flow rate, incomplete emptying of the bladder and getting up at night to
urinate (nocturia). The patient scores the frequency of each problem on a
scale of 0 (not at all) to 5 (almost always). The resulting AUA Symptom Score
ranges from 0 points (no symptoms) to 35 points (severe). A score of 8 points
or more indicates moderate to severe symptoms warranting consideration of
BPH is a common disorder of older men, afflicting approximately half of
men over age 50 and close to 90% of men by age 80. The disorder causes
difficulties with urination associated with aging, such as urination at night,
urge to void frequently, hesitancy, weak stream, and other problems.
More information about Nymox is available at www.nymox.com, email:
email@example.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of 1995
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and the actual results and
future events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products involve
substantial risks and uncertainties and actual results may differ materially
from expectations. Promising early results do not ensure that later stage or
larger scale clinical trials will be successful or will proceed as expected.
Such factors are detailed from time to time in Nymox's filings with the United
States Securities and Exchange Commission and other regulatory authorities.
For further information:
For further information: Nymox Pharmaceutical Corporation Roy Wolvin,